B. Shayne Kennedy

Shayne's issuer-side representations include advising:

• CARGO Therapeutics in its initial public offering
• Inari Medical in its initial public offering
• Procept BioRobotics in its initial public offering
• Sonendo in its initial public offering
• Paragon 28 in its initial public offering
• Sana Biotechnology in its initial public offering
• Traeger in its initial public offering
• Guardant Health, Inc. in its initial public offering
• Switch, Inc. in its initial public offering
• Inspire Medical Systems in its initial public offering and subsequent public offering
• Seres Therapeutics in its initial public offering
• Entellus Medical in its initial public offering and subsequent public offering
• Radius Health in its initial public offering
• Puma Biotechnology in its initial public offering and several subsequent public offerings
• BIND Therapeutics in its initial public offering
• Aratana Therapeutics in its initial public offering
• Skullcandy in its initial public offering
• Puma Biotechnology in its private placement and concurrent reverse merger into a public shell corporation

Most recently, Shayne's underwriter side representations include:

• Goldman Sachs in connection with the IPO of Lyell Immunopharma
• JP Morgan in connection with the IPO of Silk Road Medical
• Piper Sandler & Co. in connection with the IPO of Nyxoah
• JP Morgan Securities in connection with the IPO of Minerva Surgical
• Citigroup Global Markets, Inc. in connection with the IPO of Shattuck Labs
• Bank of America Merrill Lynch and JP Morgan in connection with the IPO of Avedro
• Citigroup and SVB Leerink in connection with the IPO of Harpoon Therapeutics
• Goldman Sachs and JP Morgan in connection with the IPO of Allogene Therapeutics
• JP Morgan and Cowen in connection with the IPO of Twist Bioscience
• Bank of America Merrill Lynch in connection with the IPO of Principia Biopharma
• Jefferies in connection with the IPO of Kezar Life Sciences
• Piper Jaffray in connection with the IPO of Neuronetics
• JP Morgan in connection with the IPO of Urovant Sciences
• Other representative IPOs in which Shayne has represented the underwriters include Corium International, Intersect, Juno Therapeutics, Kindred Biosciences, LDR Holdings, Ultragenyx, Tornier, Sientra, Invuity, Glaukos, Cellectis, Fluidigm, Obalon Therapeutics, and Fulgent Genetics

Shayne's extensive capital markets experience also includes the representation of both underwriters and issuers in public and private offerings for Allergan, Amarin, American Medical Systems Holdings, Array Biopharma, Dyax, BioMarin, Ceradyne, Dexcom, Gilead Sciences, Green Plains Renewable Energy, Kaiser Aluminum, Mako Surgical, Mannkind, Medivation, MSC Software, MyoKardia, Neurogen, Oclaro, Radius Health, ResMed, Resources Connection, Seattle Genetics, UniLife, VNUS Medical Technologies, Volcano, Volcom, Wright Medical, YM Biosciences, and ZIOPHARM Oncology.

Shayne's underwriting clients include Citigroup, Credit Suisse, Deutsche Bank Securities, Jefferies & Company, JP Morgan, BofA Merrill Lynch, Morgan Stanley, Piper Jaffray, Roth Capital Partners, and Stifel.

Shayne continues to provide outside corporate counsel to various public and private companies including Puma Biotechnology, Guardant Health, Inspire Medical, Obalon Therapeutics, Hart, and Novo A/S.